US4837111A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Dosage form for dispensing drug for human therapy
Assignee: Alza Corp
•
Filing: 1988-03-21
•
Granted: 1989-06-06
•
Expires: 2008-03-21
Abstract
Abstract An osmotic dosage system is disclosed for delivering the therapeutically beneficial drug doxazosin to an environment of use over time.
Inventors
- 👤 Joseph C. Deters
- 👤 Patrick S. L. Wong
- 👤 Brian L. Barclay
- 👤 Felix Theeuwes
- 👤 David R. Swanson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 22:19
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0002; A61K9/0004; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61P; A61P25/00; A61P25/02
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
148 words
An osmotic device for administering a therapeutically effective amount of doxazosin to an environment of use, the osmotic device comprising: (a) a wall comprising in at least a part a cellulose acetate composition permeable to the passage of an exterior fluid, which wall surrounds and forms; (b) a compartment; (c) a first composition in the compartment, said first composition comprising from 1 to 25 mg of doxazosin, from 250 to 325 mg of polyethylene oxide, and from 10 to 30 mg of hydroxypropylmethylcellulose; (d) a second composition in the compartment, said second composition comprising from 110 to 140 mg of polyethylene oxide, from 40 to 70 mg of sodium chloride, and from 5 to 25 mg of hydroxypropylmethylcellulose; and, (e) at least one passageway in the wall communicating with the compartment and the exterior of the device for delivering the therapeutic drug doxazosin to the environment of use.
Claim 2
Dependent Claim
148 words
An osmotic device for administering a therapeutically effective amount of doxazosin to an environment of use, the osmotic device comprising: (a) a wall comprising in at least a part a cellulose acetate composition permeable to the passage of an exterior fluid, which wall surrounds and forms; (b) a compartment; (c) a first composition in the compartment, said first composition comprising from 1 to 25 mg of doxazosin, from 250 to 325 mg of polyethylene oxide, and from 10 to 30 mg of hydroxypropylmethylcellulose; (d) a second composition in the compartment, said second composition comprising from 110 to 140 mg of polyethylene oxide, from 40 to 70 mg of sodium chloride, and from 5 to 25 mg of hydroxypropylmethylcellulose; and, (e) at least one passageway in the wall communicating with the compartment and the exterior of the device for delivering the therapeutic drug doxazosin to the environment of use.
Claim 3
Dependent Claim
50 words
The osmotic device for administering doxazosin according to claim 1, wherein the first composition comprises 2.4 mg of doxazosin mesylate, 83 mg of polyethylene oxide having a 100,000 molecular weight, 56 mg of polyethylene oxide having a 200,000 molecular weight, and 7.5 mg of hydroxypropylmethylcellulose having a 11,300 molecular weight.
Claim 4
Dependent Claim
50 words
The osmotic device for administering doxazosin according to claim 1, wherein the first composition comprises 4.8 mg of doxazosin mesylate, 83 mg of polyethylene oxide having a 100,000 molecular weight, 56 mg of polyethylene oxide having a 200,000 molecular weight, and 7.5 mg of hydroxypropylmethylcellulose having a 11,300 molecular weight.
Claim 5
Dependent Claim
50 words
The osmotic device for administering doxazosin according to claim 1, wherein the first composition comprises 9.6 mg of doxazosin mesylate, 166 mg of polyethylene oxide having a 100,000 molecular weight, 111 mg of polyethylene oxide having a 200,000 molecular weight and 15 mg of hydroxypropylmethylcellulose having a 11,300 molecular weight.
Claim 6
Dependent Claim
40 words
The osmotic device for administering doxazosin according to claim 1, wherein the second composition comprises 64.5 mg of polyethylene oxide having a 7,500,000 molecular weight, 29 mg of sodium chloride, and 5 mg of hydroxypropylmethylcellulose having a 11,300 molecular weight.
Claim 7
Dependent Claim
39 words
The osmotic device for administering doxazosin according to claim 1, wherein second composition comprises 129 mg of polyethylene oxide having a 7,500,000 molecular weight, 58 mg of sodium chloride, and 10 mg of hydroxypropylmethylcellulose having a 11,300 molecular weight.
Claim 8
Dependent Claim
21 words
The osmotic device for administering doxazosin according to claim 1, wherein the first composition comprises about 2.6 mg of doxazosin mesylate.
Claim 9
Dependent Claim
21 words
The osmotic device for administering doxazosin according to claim 1, wherein the first composition comprises about 5.3 mg of doxazosin mesylate.
Claim 10
Dependent Claim
21 words
The osmotic device for administering doxazosin according to claim 1, wherein the first composition comprises about 10.6 mg of doxazosin mesylate.
Claim 11
Dependent Claim
40 words
The osmotic device for administering doxazosin according to claim 1, wherein the second composition comprises 64.5 mg of polyethylene oxide having a 5,000,000 molecular weight, 29 mg of sodium chloride, and 5 mg of hydroxypropylmethylcellulose having a 11,300 molecular weight.
References Cited (Backward Citations)
US3845770A
Cited
US3916899A
Cited
US4111202A
Cited
US4235236A
Cited
US4309996A
Cited
US4320759A
Cited
US4532135A
Cited
US4765989A
Cited
US4760057A
Cited
US4758569A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-06-05 | 1992-12-05 | 1993-06-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-06-05 | 1996-12-05 | 1997-06-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-06-05 | 2000-12-05 | 2001-06-06 | $7700.00 | Window Closed / Lapsed |